DOI: http://dx.doi.org/10.18203/2349-3933.ijam20220124

Study of serum C-peptide levels in newly diagnosed diabetic mellitus subjects of North Gujarat region of India

Rashidkhan B. Pathan, Niravkumar H. Purohit, Prema Ram Choudhary

Abstract


Background: Serum C-peptide has appeared as the chief clinical and practically adequate marker of β-cell function of pancreas. Serum insulin and C-peptide are concomitantly secreted into the blood circulation in equal amount. The aim of the study was to determine serum C-peptide levels in newly diagnosed diabetic mellitus subjects of North Gujarat region of India.

Methods:The present cross-sectional study was done on 50 subjects of recently diagnosed Diabetes mellitus (T2DM) and non-diabetic healthy controls at Banas Medical College and our trust-based hospital. All diabetics patients were further classified into two groups; normal FC group consist of subjects with FC level 0.5-3.2 ng/ml (N=14) and high FC group included subjects with FC>3.2 ng/ml (N=36). The patients' demographic and anthropometric parameters were recorded; detailed history and clinical examination were performed in the entire cases. All biochemical parameters were analyzed.  

Results: Predominance of the T2DM subjects was in the age group of 41-50 years. Mean value for age (p<0.01), anthropometric (p<0.01), fasting plasma glucose (p<0.001), HbA1c (p<0.01), cholesterol (p<0.01), triglycerides (p<0.001) and C-peptide (p<0.001) were significantly higher in the T2DM subjects. The mean values of fasting plasma glucose (p<0.001) and HbA1c (p<0.01) are significantly higher in T2DM subject with high C-peptide level as compared to normal C-peptide level.  

Conclusions:In our study, we conclude that elevated levels of fasting C-peptide in newly diagnosed T2DM. Therefore, we suggested that serum C-peptide levels are valuable as marker of endogenous insulin production from β-cell of pancreas.


Keywords


Diabetes mellitus, C-peptide, BMI, Endogenous insulin

Full Text:

PDF

References


American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(1):13-28.

WHO, International Health Federation. The Diabetes Action Now. Geneva: WHO; 2004.

WHO. The World Health Report. Available at: https://www.who.int/whr/2010/10_su. Accessed on 28 December 2021.

Siraj ES, Reddy SS, Scherbaum WA, Abdulkadir J, Hammel JP, Faiman C. Basal and postglucagon C-peptide levels in Ethiopians with diabetes. Diabetes Care. 2002;25(3):453-7.

Bamashmos M. Relationship between c-peptide and chronic complications in yemini type 2 diabetic patients. J Bio Innov. 2018;7(6):922-32.

Vlad A, Serban V, Sima A, Timar R, Roşu M. The value of basal C peptide and its relationship with pancreatic autoantibodies in young adults with type 2 diabetes mellitus. Rom J Intern Med. 2004;42(2):333-41.

Ko GT, So WY, Tong PC, Chan WB, Yang X, Ma RC, et al. Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ. 2009;180(9):919-26.

Haban P, Simoncic R, Zidekova E, Ozdin L. Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. Med Sci Monit. 2002;8(3):175-9.

Usmani R, Gupta BK, Kaur J. Serum C-peptide and insulin levels in patients of metabolic syndrome. Int J Clinic Biochem Res. 2016;3(4):482-6.

International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Belgium: International Diabetes Federation; 2015.

Sharma A, Kaur J, Uppal V, Singh I. Correlation of Serum C-Peptide and Serum uric acid Levels with Glycated Hemoglobin in Patients of Type 2 DM. Int J Clinical Biochem Res. 2016;3(3):330-4.

Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8(3):475-87.

Hasan ABM, Fariduddin M, Ghosh DK, Islam, Rahman M, Sultana, et al. Vitamin B12 is Found Sufficient in Newly Diagnosed Type 2 Diabetes in a Hospital Based Study. Int J Diabetes Metab Disord. 2016;1(1):1-5.

Fronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 DM. Diabetes. 2009;58(4):773-95.

Mariyam SB, Muthubeevi SB, Vasantha SC. Serum C-Peptide level in obese and non-obese patients with type 2 DM. J Evolution Med Dent Sci. 2017;6(5):350-3.